471 Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma

Basosquamous carcinoma (BSC) is an aggressive skin neoplasm with features of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). While genetic and molecular drivers of BCC and SCC development have been extensively characterized, BSC pathogenesis remains unclear, in particular regarding the reprogramming of tumor keratinocytes towards basaloid or squamatized phenotypes. Here, by analogy to pathway switching previously observed in BCC escaping Hedgehog (Hh) inhibition, we demonstrate loss of Hh signaling and MAPK pathway activation associated with squamatization of BSC.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Melanoma and Other Skin Cancers Source Type: research

Related Links:

In the last two decades, the U.S. has seen a dramatic rise in the rates of both melanoma and non-melanoma skin cancers, which are linked to ultraviolet radiation exposure.1 Non-melanoma skin cancer, which include basal cell carcinoma and squamous cell carcinoma, are the most common malignancies in the U.S.. Melanoma is the fifth most common cancer, and it has been projected that nearly 100,000 new cases of melanoma will be diagnosed in this country by the end of 2019.2
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Review Source Type: research
Abstract Skin cancer is a broad term used to describe a number of different malignant indications of the skin. Skin cancers mostly comprise of the keratinocyte cancers [Basal Cell Carcinoma (BCC) and cutaneous Squamous Cell Carcinoma (SCC)], and melanoma. Surgical excision of these malignancies has been the preferred treatment of patients for decades. However, the decision to perform surgery can be affected by various considerations, including co-morbidities of the patient, the anatomical site of the lesion and potential intolerance for repeated excisions. Topical treatment of skin cancer may therefore be more app...
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Tags: Adv Drug Deliv Rev Source Type: research
ConclusionsThe use of NSAIDs might reduce the risk of SC, but many factors including study population, drug subtype, and disease subclass affect the significance of the association.Graphical abstract
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
In this report, we analyzed gene expression profiles of paired specimens of keratinocyte carcinomas with their matched normal skin tissues as the control. Among several novel findings, we discovered a significant number of zinc finger encoding genes up-regulated in human BCC. In BCC, a novel link was found between hedgehog signaling, Wnt signaling, and the cilium. While the SCC cancer-stem-cell gene signature is shared between human and mouse SCCs, the hair follicle stem-cell signature of mice was not highly represented in human SCC. Differential gene expression (DEG) in human BCC shares gene signature with both bulge and ...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
Authors: deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Ståhle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C, Srivastava B, Krueger G Abstract To the Editor: Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated among those who previously received systemic treatment or phototherapy.2 Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase suscept...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Non-melanoma skin cancer (NMSC) is the most common cancer worldwide. Australia has the highest incidence of skin cancer in the world, exceeding 2000 per 100  000 person-years and it is increasing [1]. In the USA, more than 3 million individuals are diagnosed with NMSC each year [2,3]. In the UK, during 2014–2016, about 147 000 new NMSC cases were diagnosed every year, more than 400 every day [4]. Data show that between 1976 and 1984, the overall inc idence of basal cell carcinoma (BCC) increased by 145% and of cutaneous squamous cell carcinoma (cSCC) by 263%.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Editorial Source Type: research
Transplant recipients have a significantly higher risk of developing non-melanoma skin cancers compared with the general population and squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common post-transplant malignancies. Although in the general population BCC outnumbers SCC 4:1, in transplant patients this ratio is reversed and SCC is more common, with a 65- to 250-fold increased incidence. As patients in immunosuppressed states are living longer after transplants, the incidence of skin cancer in this population continues to increase.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Overview Source Type: research
Cyclooxygenase-2 (COX-2) inhibitor has been associated with lower risk of several cancers, but epidemiological studies on skin cancer risk have been limited and inconclusive. COX-2 inhibitor use and risk of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma were evaluated in three prospective cohorts - the Nurses ’ Health Study (NHS, 2000-2012), NHS II (2001-2011), and the Health Professionals Follow-up Study (HPFS, 2002-2012). COX-2 inhibitor use and skin cancer incidence were assessed using biennial questionnaires, with cSCC and melanoma cases verified by pathological records.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
Abstract Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board-approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, po...
Source: The American Surgeon - Category: Surgery Authors: Tags: Am Surg Source Type: research
Facial plast Surg 2019; 35: 368-376 DOI: 10.1055/s-0039-1695044The European Academy of Facial Plastic Surgery celebrates its 40th anniversary. We aimed to describe innovations in the diagnostics and treatment in head and neck skin cancer over the past 40 years as well as future perspectives. Landmark events, developments, and highlights over the past decades for basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma are discussed. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Facial Plastic Surgery - Category: Cosmetic Surgery Authors: Tags: Original Article Source Type: research
More News: Basal Cell Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Dermatology | Genetics | Melanoma | Skin | Skin Cancer | Squamous Cell Carcinoma